ArticleOphthalmology science2026
Progression of Macular Tissue Loss in Choroideremia and Its Association with Baseline Fundus Autofluorescence Morphology.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterize short-term progressive loss of macular preserved autofluorescence (PAF) in choroideremia and to determine how baseline PAF morphology influences subsequent structural decline. Design: Post hoc longitudinal analysis of a multicenter prospective natural history cohort (NIGHT study). Participants: A total of 106 participants (163 eyes) with genetically confirmed choroideremia and gradable fundus autofluorescence (FAF) imaging at baseline and month 12. Methods: Regions of PAF were manually segmented on FAF images and converted into binary masks. Total PAF area and PAF perimeter were quantified at baseline and month 12 using an automated ImageJ based workflow. Associations between baseline characteristics (PAF area, perimeter, foveal status, and PAF region focality) and 12 months PAF change were evaluated using linear mixed effects models accounting for intereye correlation. Main Outcome Measures: Change in total macular PAF area over 12 months and its association with baseline PAF region characteristics. Results: Mean PAF area decreased significantly from 3.77 ± 4.53 mm Conclusions: Macular PAF area measured by FAF demonstrated significant decline over 12 months in choroideremia and may represent a useful structural endpoint for assessing short-term disease progression. Larger baseline PAF area and perimeter were associated with greater subsequent PAF loss. These findings may improve understanding of disease natural history and inform the design of future clinical trials. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.